Full history for every metric is available with a Kvantra account
Eurofins-Cerep S.A. (ALECR.PA)
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 33 | 42 | 48 | 44 | 40 | 41 | 41 |
| Operating profit | €m | 3 | 3 | |||||
| Net profit | €m | 6 | 10 | 12 | 8 | 7 | 5 | 5 |
| EPS reported | € | 948.2 | 948.2 | |||||
| Operating cashflow per share | € | 0.00 | -631.8 | |||||
| Capex per share | € | 0.00 | 90.80 | |||||
| FCF per share | € | 0.00 | -722.6 | |||||
| Free cash flow | €m | - | -4 | |||||
| Net debt | €m | -21 | -21 | |||||
| Book value equity | €m | 76 | 76 | |||||
| Book value per share | € | 15,138 | 15,138 | |||||
| Number of shares | m | 0.01 | 0.01 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 18.77 | - | |||||
| P/B LTM | x | 1.18 | 1.06 | |||||
| P/S LTM | x | 2.19 | 1.98 | |||||
| P/FCF LTM | x | 0.00 | -22.28 | |||||
| EV/EBITDA LTM | x | 15.42 | 9.82 | |||||
| EV/Sales LTM | x | 1.97 | 1.47 | |||||
| Earnings Yield LTM | % | 5.33% | 5.89% | |||||
| FCF Yield | % | 0.00% | -4.49% | |||||
| Quality | ||||||||
| ROE | % | 6.26% | 6.38% | |||||
| ROIC | % | 3.64% | 3.89% | |||||
| Operating margin | % | 6.99% | 7.48% | |||||
| Gross margin | % | 16.56% | 16.56% | |||||
| FCF/Sales | % | 0.00% | -8.90% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -33.15% | -33.15% | |||||
| Sales Growth YoY | % | +1.28% | +1.28% | |||||
| Net Income Growth YoY | % | -33.15% | -33.15% | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | -36.35% | -36.35% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | -474.55 | |||||
| Net Debt/EBITDA | x | -1.74 | -1.49 | |||||
| EBIT/Net interest | x | 291.43 | 311.57 | |||||
| Net debt/market cap | % | -23.43% | -25.90% | |||||
| Net debt/Equity | x | -0.28 | -0.28 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the management of chemical compounds, high-throughput screening capabilities, in vitro safety assessments, optimization of lead compounds (SAR profiling), in vitro ADME evaluations, and in vivo pharmacokinetic (PK) studies. Furthermore, it provides expert services in assay development and design. The organization, originally known as Cerep SA, officially adopted the name Eurofins Cerep SA in June 2014.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Eurofins-Cerep S.A. (ALECR.PA)
Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the management of chemical compounds, high-throughput screening capabilities, in vitro safety assessments, optimization of lead compounds (SAR profiling), in vitro ADME evaluations, and in vivo pharmacokinetic (PK) studies. Furthermore, it provides expert services in assay development and design. The organization, originally known as Cerep SA, officially adopted the name Eurofins Cerep SA in June 2014.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free